No Data
No Data
Warrant Pharmaceutical Gets Marketing License for Terbutaline Sulfate Nebulized Inhalation Solution; Shares Rise 4%
Warner Pharmaceuticals (688799.SH): The pharmaceutical supplementary application approval notice for the aerosol inhalation solution of terbutaline sulfate has been obtained.
On October 17, Gelonghui announced that Warner Pharmaceutical Factory (688799.SH) received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration regarding the change of the pharmaceutical license holder for the market approval of the pharmaceutical solution of terbutaline sulfate for inhalation. Terbutaline sulfate inhalation solution is suitable for relieving bronchial asthma, chronic bronchitis, emphysema, and bronchospasm associated with other pulmonary diseases.
Warner Pharmaceuticals (688799.SH) plans to distribute 0.9 yuan per share in 2023, with ex-rights and ex-dividends on October 25th.
Warner Pharmaceutical Factory (688799.SH) announced that the company plans to distribute a cash dividend of 0.90 yuan per share for the 2023 fiscal year...
Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Price Is Right But Growth Is Lacking After Shares Rocket 38%
Hunan Warrant Pharmaceutical Completes Phase 1 Study for Antidepressant
Warner Pharmaceutical Factory (688799.SH): Subsidiary ZG-001 Capsule completes Phase I clinical trial and signs a cooperation framework agreement.
On September 30, Gracell announced that its holding subsidiary, Shanghai Zhigen Pharmaceutical Technology Co., Ltd., has recently completed Phase I clinical trials for project ZG-001 capsules under the approval of the National Medical Products Administration. Zhigen Pharmaceutical and Peking University Affiliated An Ding Hospital (referred to as "An Ding Hospital") have signed a "Cooperation Framework Agreement" for joint development of the ZG-001 project on the mainland of China. ZG-001 capsules are a new type of antidepressant with a completely new structure independently developed by Zhigen Pharmaceutical, classified as a class 1 new drug. ZG-001 is intended for the treatment of adult depression.
No Data
No Data